Ascentage Pharma Group International
NASDAQ:AAPGBiotechnology
+$0.31 today
- Market cap
- $1.21B
- Beta
- 0.65
- P/E (TTM)
- -8.9
- EPS (TTM)
- -$13.29
Volume 0.00M
Average 0.01M
AAPG Deferred Revenue
Payments received for goods or services the company will deliver within the next year.
Ascentage Pharma Group InternationalNASDAQ: AAPG
Deferred Revenue · Q4 FY2025 · quarter ended Dec 2025
Deferred revenue falls 30.6% from a year ago
Deferred revenue stood at CN¥37.51M at the end of Q4 FY2025, down 30.6% from a year earlier. Over 3 fiscal years it compounded at +15.5% a year.
Context
- Deferred revenue amounted to 0.9% of total assets at the end of Q4 FY2025, down 1.1 pp from a year earlier.
- Deferred revenue increased in 2 of the last 3 fiscal years.
What to watch
Whether deferred revenue keeps falling in the next quarterly balance sheet after a -30.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Deferred Revenue history
CNY · from the balance sheet
- Latest · FY2025
- 37.51M CNY
- Year-over-year change
- -30.6%
| Period | Period end | Deferred Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 37.51M | -30.6% |
| FY2024 | 2024-12-31 | 54.09M | +40.8% |
| FY2023 | 2023-12-31 | 38.41M | +57.7% |
| FY2022 | 2022-12-31 | 24.35M | — |
| FY2021 | 2021-12-31 | 0 | — |
Deferred Revenue vs competitors
How AAPG compares with its peers on the latest reported figures
- Peers report in different currencies, so deferred revenue is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -30.6% is the 2nd highest of 5, against a peer median of -60.0%.
- Deferred revenue amounts to 0.9% of total assets for AAPG, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
AAPGAscentage Pharma Group International | Dec 2025 | CN¥37.51M CNY | -30.6% | +15.5% | 0.9% |
| Jun 2026 | $27.5M USD | — | — | 2.6% | |
| Mar 2026 | $10.12M USD | -53.1% | -9.1% | 3.1% | |
| Jun 2026 | $8.86M USD | -8.9% | — | 1.2% | |
| Aug 2026 | $8.61M USD | -66.9% | -22.4% | 0.7% | |
| Sep 2026 | $0 USD | — | — | 0.0% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Dec 2025 | $0 USD | -100.0% | — | 0.0% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Peer median (excluding AAPG) | — | -60.0% | -15.7% | 0.0% | |
Competitors are the stored peer set for AAPG. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 1.71B | 1.48B | 1.07B | 1.24B | 2.47B |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 54.13M | 61.49M | 163.54M | 99.07M | 253.1M |
| Inventory | 3.93M | 9.45M | 16.17M | 6.6M | 28.64M |
| Other Current Assets | 59.26M | 16.6M | 24.54M | 24.63M | 192.65M |
| Total Current Assets | 1.89B | 1.64B | 1.34B | 1.47B | 2.95B |
| Property, Plant & Equipment (Net) | 854.3M | 650.03M | 957.23M | 905.86M | 829.59M |
| Goodwill | 24.69M | 24.69M | 24.69M | 24.69M | 24.71M |
| Intangible Assets | 60.41M | 84.3M | 85.45M | 76M | 65.98M |
| Long-term Investments | 27.85M | 18.53M | 18.95M | 33.86M | 37.05M |
| Tax Assets | 51.65M | 54.29M | 59.84M | 44.24M | 31.98M |
| Other Non-current Assets | 35.88M | 361.93M | 10.05M | 59M | 30.74M |
| Total Non-current Assets | 1.05B | 1.19B | 1.16B | 1.14B | 1.02B |
| Total Assets | 2.94B | 2.83B | 2.5B | 2.62B | 3.97B |
| Account Payables | 70.86M | 95.56M | 72.45M | 91.97M | 106.81M |
| Short-term Debt | 39.8M | 510.31M | 606.65M | 769.62M | 1.22B |
| Tax Payables | 3.28M | 7.18M | 8.39M | 9.63M | 0 |
| Deferred Revenue | 0 | 24.35M | 38.41M | 54.09M | 37.51M |
| Other Current Liabilities | 58.73M | 2.82M | 0 | 0 | 276.84M |
| Total Current Liabilities | 361.11M | 881.15M | 934.17M | 1.17B | 1.64B |
| Long-term Debt | 1.03B | 1.27B | 1.17B | 868.64M | 742.8M |
| Deferred Tax Liabilities | 13.75M | 12.15M | 10.55M | 5.37M | 0 |
| Deferred Revenue (Non-current) | 243.28M | 218.63M | 287.55M | 275.96M | 216.86M |
| Other Non-current Liabilities | 52.34M | 35.33M | 18.3M | 6.27M | 12.04M |
| Total Non-current Liabilities | 1.34B | 1.54B | 1.5B | 1.18B | 986.62M |
| Total Liabilities | 1.71B | 2.42B | 2.43B | 2.34B | 2.63B |
| Common Stock | 178K | 180K | 197K | 214K | 256.16K |
| Retained Earnings | (3.56B) | (4.44B) | (5.37B) | (5.77B) | 0 |
| Accumulated OCI | (550.95M) | (518.51M) | (504.46M) | (510.59M) | 1.33B |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 10.22M | 9.97M | 9.76M |
| Total Equity | 1.23B | 408.66M | 70.63M | 274.16M | 1.34B |
| Total Debt | 1.08B | 1.79B | 1.8B | 1.67B | 1.98B |
| Net Debt | (622.6M) | 317.09M | 726.3M | 431.92M | (490.68M) |
Ascentage Pharma Group International
NASDAQ:AAPG
Intrinsic Alpha fair value
Locked
Current Price
$13.01
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.